logo
episode-header-image
Nov 2020
31m 18s

How I treat NSCLC in the era of checkpoi...

MEDSCAPE PROFESSIONAL NETWORK
About this episode

In this episode, we review how immune checkpoint inhibitors and COVID-19 have changed the management of non-small cell lung cancer (NSCLC). Jeffrey Crawford, MD, and Susan Blackwell, PA, both of Duke Cancer Institute, join host David H. Henry, MD, to discuss the use of pembrolizumab in NSCLC, two studies of PD-1 inhibitors presented at ESMO 2020, and how COVID-19 has affected NSCLC care, particularly the use of granulocyte colony-stimulating factor (G-CSF). Diagnosis and treatment of NSCLC What information should be obtained from a biopsy?

  • Is this lung cancer?
  • If so, what kind of lung cancer is it: Small-cell lung cancer or NSCLC? Which subtype?
  • Molecular studies for targets, including ALK, KRAS, EGFR, PD-L1.

Treatment with pembrolizumab:

  • If, for example, a patient has NSCLC and is positive for PD-L1, the treatment of choice is pembrolizumab.
  • A multidisciplinary approach is essential to provide comprehensive education and care to patients taking pembrolizumab (and other immunotherapies).
  • Pembrolizumab can have many side effects, including itching, fatigue, thyroiditis progressing to hypothyroidism, hypophysitis, or another off-target “-itis.”
  • Ms. Blackwell and Dr. Crawford recommend listening to patients, checking the thyroid routinely, and checking cortisol based on index of suspicion.

NSCLC studies presented at ESMO 2020 KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50%.

  • The 5-year survival is greater than 30% with pembrolizumab in this study.
  • Historically, 5-year survival has been 1% to 2% in patients treated with chemotherapy alone, Dr. Crawford said.
  • In the control arm of this study, patients received chemotherapy and then crossed over into the pembrolizumab arm, so overall survival was 16% at the 5-year mark.
  • The results suggest immunotherapy should be used first-line if patients meet criteria, Dr. Crawford said.
  • Source: Abstract LBA51. https://bit.ly/3mMYLTK.

EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%. 

  • Cemiplimab improved overall and progression-free survival in NSCLC patients when compared with chemotherapy alone.
  • Abstract LBA52. https://bit.ly/3mLT6xb.

The effects of COVID-19 on NSCLC care

Logistically, it’s more difficult to see patients during the pandemic, Dr. Crawford noted, but the many potential side effects of immunotherapy make it necessary to see patients regularly in person. How has COVID-19 affected the concern of febrile neutropenia and the use of G-CSF? Dr. Crawford said the pandemic has heightened the concern about infection risk. Prior guidelines for G-CSF:

  • Before the pandemic, guidelines suggested routine prophylactic G-CSF in patients with a greater than 20% risk of febrile neutropenia.
  • In patients with 10% to 20% risk, the recommendation was to consider the use of G-CSF based on the patient population and risk factors.

Pandemic-specific guidelines for G-CSF:

  • The National Comprehensive Cancer Network (NCCN) recommended relaxing guidelines during the pandemic.
  • If the risk is greater than 20%, NCCN still recommends giving G-CSF.
  • If the risk is 10% to 20%, NCCN recommends giving G-CSF even in the absence of additional risk factors.
  • Dr. Crawford noted that lung cancer patients receiving chemotherapy are typically in the 10% to 20% risk category.
  • Download the COVID-specific NCCN guidelines: https://bit.ly/3jQIco5.

G-CSF biosimilars

  • The most common complaint with biosimilars is bone pain.
  • Ms. Blackwell advises first treating bone pain with acetaminophen or ibuprofen and warm blankets.
  • For refractory pain, she suggests a low-dose narcotic or dexamethasone.
  • Consider an antihistamine for prophylaxis, as patients report this can help with symptoms.

Show notes written by Ronak Mistry, DO, a resident at Pennsylvania Hospital, Philadelphia.

Disclosures: Dr. Crawford is on advisory boards at Amgen and Merck, makers of Onpro/Neulasta (pegfilgrastim) and Keytruda (pembrolizumab). Ms. Blackwell and Dr. Henry have no conflicts of interest.

* * *

For more MDedge podcasts, go to mdedge.com/podcasts

Email the show: podcasts@mdedge.com

Interact with us on Twitter: @MDedgehemonc

David Henry on Twitter: @davidhenrymd

Up next
May 2021
Biosimilars with Dr. Gary Lyman
Existing biosimilars are safe, effective alternatives to their reference biologics, and are increasingly being incorporated into oncology treatment guidelines. Technological advances that have emerged in the years since biologic agents entered the market allow for the careful ass ... Show More
32m 6s
May 2021
Advanced bladder cancer: Dr. Arjun Balar talks treatment strategies in a changing field
Systemic treatment for advanced urothelial cancer is quickly evolving. On this week’s podcast, Arjun Balar, MD, director of the genitourinary medical oncology program at New York University discusses his approach amid changing times with guest host Alan Lyss, MD, a community-base ... Show More
27m 25s
May 2021
Gene therapies in hemophilia with Dr. Glenn Pierce
A “very basic” type of gene therapy could potentially cure hemophilia, but a major hurdle has been the lack of an effective mode of delivery. Recent strides in using adeno-associated virus (AAV) vectors are changing that, and Glenn Pierce, MD, World Federation of Hemophilia Vice ... Show More
24m 10s
Recommended Episodes
Sep 2019
Job satisfaction among dermatology hospitalists; plus understanding your millennial patients, and treating infections in atopic dermatitis
More patients are being admitted to the hospital with skin problems, and specialized dermatologists are needed to provide effective treatment. Dr. Vincent DeLeo talks with Dr. Michi M. Shinohara about the evolving role of the dermatology hospitalist in the inpatient setting. Dr. ... Show More
17m 9s
May 26
Why Your Skin Is Begging You to Heal Your Gut First
Skin issues like acne, eczema, and rosacea are deeply connected to internal imbalances, especially those originating in the gut. It is important to explore diet—particularly sugar, refined carbs, and dairy—because it can drive inflammation, insulin resistance, and hormonal disrup ... Show More
53m 56s
Sep 2024
#126: Dermatology in Greece Part III - Promoting Health through Cosmetic Dermatology
In this episode, we talk with Dr. Fotini Bageorgou, MD. Dr. Bageorgou is an internationally renowned dermatologist, specifically for her work in cosmetic dermatology. Dr. Bageorgou is currently honored to be president of the International Peeling Society. Dr. Bageorgou tells us a ... Show More
49m 51s
May 2024
PRETTY CURIOUS | What’s the Deal with Psoriasis?
We’re getting personal on this episode of Pretty Curious with Jonthan’s dermatologist, Dr. Ali Shahbaz! The two walk through Jonthan’s psoriasis journey and along the way, Dr. Shahbaz answers all our questions like what are the different types of psoriasis, what are some common t ... Show More
45m 57s
Mar 2021
Treating Adult Acne & Rosacea From The Inside Out with Dr. Todd LePine
Treating Adult Acne & Rosacea From The Inside Out | This episode is sponsored by ButcherBox and AquaTru Our skin is a reflection of what’s going on with our health beneath the surface; skin problems often signal that something is off in our body. Acne rosacea is an inflammatory c ... Show More
43m 30s
Jan 2025
Heart Disease, Hormones & LPa Explained by Dr. Darshan Shah
Dr. Darshan Shah reveals the shocking truth about the prevalence and danger of high Lp(a), citing personal anecdotes and expounding on how lifestyle changes, though beneficial, aren't always enough to mitigate the risks associated with this particular marker. The episode delves i ... Show More
1h 1m
Apr 2020
136: Alternative Solutions For Rosacea w/ Dr. Peter Lio
Rosacea is a skin condition best known for causing redness and flushing. But is can also lead to pustules and comedones. My guest today will share more about rosacea, as well as possible treatment options. My guest today is Dr. Peter Lio, a Clinical Assistant Professor of Dermato ... Show More
27 m
Feb 2024
The Science of Resilience: How You Can Heal From Within | Dr. Domenick Sportelli
Dr. Sportelli is a Medical Physician who received a Bachelors degree in Biology as well as a Masters of Science degree in Biology from Montclair State University. He attended NYIT School of Osteopathic Medicine, and upon graduating with Honors in clinical science, Dr. Sportelli p ... Show More
1h 53m
Sep 2024
Beyond the Digest: September 2024
Beyond the Digest are bonus episodes to the DermSurgery Digest that include reviews of interesting and relevant articles in dermatologic surgery literature. This episode features articles from the Journal of the National Comprehensive Cancer Network(JNCCN), the Journal of the Ame ... Show More
32m 45s
Oct 2024
Is Your Skincare More Important Than This?
Get Dr. Mina's free PDF on How to create Healthy Skin Habits here. Between juggling demanding careers, personal goals, and family responsibilities, it’s easy to get caught up in the hustle. But here’s the thing: all that busyness affects more than just our stress levels; it impac ... Show More
15m 28s